Human recombinant Sema3A (0.7 mg/kg/2-weekly) was administered in young mice 2 days after the local paratibial injection of parental human KHOS osteosarcoma cells (1.0 × 106) and continued until day 21. Here, SEMA3A is linked to osteosarcoma.